Predicting drug metabolism: experiment and/or computation?

[1]  B. Testa.  Organic Stereochemistry. Part 7. The Concept of Substrate Stereoselectivity in Biochemistry and Xenobiotic Metabolism , 2013 .

[2]  G. Cruciani,et al.  MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. , 2005, Journal of medicinal chemistry.

[3]  T. Nikolskaya,et al.  A COMBINED APPROACH TO DRUG METABOLISM AND TOXICITY ASSESSMENT , 2006, Drug Metabolism and Disposition.

[4]  P. Tavan,et al.  Ligand Binding: Molecular Mechanics Calculation of the Streptavidin-Biotin Rupture Force , 1996, Science.

[5]  David S. Wishart,et al.  Online Databases and Web Servers for Drug Metabolism Research , 2014 .

[6]  Spencer R Pruitt,et al.  Fragmentation methods: a route to accurate calculations on large systems. , 2012, Chemical reviews.

[7]  Mingshe Zhu,et al.  Recent advances in applications of liquid chromatography-tandem mass spectrometry to the analysis of reactive drug metabolites. , 2009, Chemico-biological interactions.

[8]  Petra Schneider,et al.  Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus , 2014, Proceedings of the National Academy of Sciences.

[9]  Hannu Raunio,et al.  Prodrugs—from Serendipity to Rational Design , 2011, Pharmacological Reviews.

[10]  G. Patlewicz,et al.  An evaluation of the implementation of the Cramer classification scheme in the Toxtree software , 2008, SAR and QSAR in environmental research.

[11]  Ian D. Wilson,et al.  Metabolite Detection and Profiling , 2014 .

[12]  G. Nagy,et al.  Rationalization of stereospecific binding of propranolol to cytochrome P450 2D6 by free energy calculations , 2012, European Biophysics Journal.

[13]  Isabelle Ragueneau-Majlessi,et al.  A useful tool for drug interaction evaluation: The University of Washington Metabolism and Transport Drug Interaction Database , 2010, Human Genomics.

[14]  György M. Keserü,et al.  Site of metabolism prediction on cytochrome P450 2C9: a knowledge-based docking approach , 2010, J. Comput. Aided Mol. Des..

[15]  Andreas Bender,et al.  The challenges involved in modeling toxicity data in silico: a review. , 2012, Current pharmaceutical design.

[16]  S. Bhatia,et al.  Microscale culture of human liver cells for drug development , 2008, Nature Biotechnology.

[17]  Rommie E. Amaro,et al.  Emerging methods for ensemble-based virtual screening. , 2010, Current topics in medicinal chemistry.

[18]  Valérie Campagna-Slater,et al.  Development of a Computational Tool to Rival Experts in the Prediction of Sites of Metabolism of Xenobiotics by P450s , 2012, J. Chem. Inf. Model..

[19]  A. Schinkel,et al.  A Critical Analysis of the Interplay between Cytochrome P450 3A and P-Glycoprotein: Recent Insights from Knockout and Transgenic Mice , 2011, Pharmacological Reviews.

[20]  Aalt Bast,et al.  Comprehensive medicinal chemistry , 1991 .

[21]  Carol A Marchant,et al.  In Silico Tools for Sharing Data and Knowledge on Toxicity and Metabolism: Derek for Windows, Meteor, and Vitic , 2008, Toxicology mechanisms and methods.

[22]  Stefan A. Mann,et al.  hERG K(+) channels: structure, function, and clinical significance. , 2012, Physiological reviews.

[23]  Pekka Tiikkainen,et al.  Estimating Error Rates in Bioactivity Databases , 2013, J. Chem. Inf. Model..

[24]  Gilles Klopman,et al.  META. 1. A Program for the Evaluation of Metabolic Transformation of Chemicals , 1994, J. Chem. Inf. Comput. Sci..

[25]  S. E. Adams.  Molecular similarity and xenobiotic metabolism , 2010 .

[26]  P. Gillman,et al.  Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. , 2005, British journal of anaesthesia.

[27]  I. Zamora,et al.  High-throughput, computer assisted, specific MetID. A revolution for drug discovery. , 2013, Drug discovery today. Technologies.

[28]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[29]  C. Esser.  5.09 – Immunotoxicology , 2007 .

[30]  Jean-Loup Faulon,et al.  The signature molecular descriptor. 3. Inverse-quantitative structure-activity relationship of ICAM-1 inhibitory peptides. , 2003, Journal of molecular graphics & modelling.

[31]  D. Kell,et al.  The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. , 2013, Drug discovery today.

[32]  F. Guengerich.  Experimental Approaches to Analysis of Reactions of Cytochrome P450 Enzymes , 2014 .

[33]  Ferenc Darvas,et al.  HazardExpert: An Expert System for Predicting Chemical Toxicity , 1992 .

[34]  David E. Gloriam,et al.  The contribution of atom accessibility to site of metabolism models for cytochromes P450. , 2013, Molecular pharmaceutics.

[35]  A. Bender.  Predicting Toxic Effects of Metabolites , 2014 .

[36]  Ferenc Darvas,et al.  Metabolexpert: An Expert System for Predicting Metabolism of Substances , 1987 .

[37]  P. Judson.  Knowledge‐Based Approaches for Predicting the Sites and Products of Metabolism , 2014 .

[38]  Jayne Kirk,et al.  Sites of metabolic substitution: investigating metabolite structures utilising ion mobility and molecular modelling. , 2010, Rapid communications in mass spectrometry : RCM.

[39]  C. Oostenbrink.  Structure‐Based Methods for Predicting the Sites and Products of Metabolism , 2014 .

[40]  R. Sheridan,et al.  A model for predicting likely sites of CYP3A4-mediated metabolism on drug-like molecules. , 2003, Journal of medicinal chemistry.

[41]  B. Testa.  Organic Stereochemistry. Part 8 , 2013 .

[42]  Timothy Clark,et al.  CypScore: Quantitative Prediction of Reactivity toward Cytochromes P450 Based on Semiempirical Molecular Orbital Theory , 2009, ChemMedChem.

[43]  Rongda Xu,et al.  Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries. , 2004, Journal of pharmaceutical and biomedical analysis.

[44]  Ying Zhang,et al.  HMDB: the Human Metabolome Database , 2007, Nucleic Acids Res..

[45]  S. Ekins,et al.  In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling , 2007, British journal of pharmacology.

[46]  Ivan S Ufimtsev,et al.  Quantum Chemistry on Graphical Processing Units. 3. Analytical Energy Gradients, Geometry Optimization, and First Principles Molecular Dynamics. , 2009, Journal of chemical theory and computation.

[47]  Ismael Zamora,et al.  Enhanced metabolite identification with MS(E) and a semi-automated software for structural elucidation. , 2010, Rapid communications in mass spectrometry : RCM.

[48]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[49]  M. Chiba,et al.  Ion Mobility Spectrometry–Mass Spectrometry Analysis for the Site of Aromatic Hydroxylation , 2013, Drug Metabolism and Disposition.

[50]  Charles H. Bennett,et al.  Efficient estimation of free energy differences from Monte Carlo data , 1976 .

[51]  B. Testa.  Organic Stereochemistry. Part 7 , 2013 .

[52]  A. Y. Lu,et al.  Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective , 2010, Drug metabolism reviews.

[53]  Johannes Kirchmair,et al.  Drug Metabolism Prediction , 2014 .

[54]  J. Kirkwood.  Statistical Mechanics of Fluid Mixtures , 1935 .

[55]  Bernard Testa,et al.  Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps. , 2009, Current opinion in chemical biology.

[56]  R. Wade,et al.  How do substrates enter and products exit the buried active site of cytochrome P450cam? 1. Random expulsion molecular dynamics investigation of ligand access channels and mechanisms. , 2000, Journal of molecular biology.

[57]  U. Holzgrabe,et al.  NMR spectroscopy in pharmaceutical and biomedical analysis. , 2014, Journal of pharmaceutical and biomedical analysis.

[58]  Ivan S Ufimtsev,et al.  Quantum Chemistry on Graphical Processing Units. 2. Direct Self-Consistent-Field Implementation. , 2009, Journal of chemical theory and computation.

[59]  Matthew J Sykes,et al.  Prediction of metabolism by cytochrome P450 2C9: alignment and docking studies of a validated database of substrates. , 2008, Journal of medicinal chemistry.

[60]  H. Rosing,et al.  Identification of drug metabolites in human plasma or serum integrating metabolite prediction, LC-HRMS and untargeted data processing. , 2013, Bioanalysis.

[61]  I. Wilson,et al.  Isotopic enrichment enhancement in metabonomic analysis of UPLC-MS data sets , 2007 .

[62]  T. Stern,et al.  Linezolid and serotonin syndrome. , 2009, Primary care companion to the Journal of clinical psychiatry.

[63]  Michael Schroeder,et al.  SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions , 2009, Nucleic Acids Res..

[64]  M. Levitt,et al.  Theoretical studies of enzymic reactions: dielectric, electrostatic and steric stabilization of the carbonium ion in the reaction of lysozyme. , 1976, Journal of molecular biology.

[65]  K. Battaile,et al.  Human Cytochrome P450 2E1 Structures with Fatty Acid Analogs Reveal a Previously Unobserved Binding Mode* , 2010, The Journal of Biological Chemistry.

[66]  Lars Ridder,et al.  Determinants of Reactivity and Selectivity in Soluble Epoxide Hydrolase from Quantum Mechanics/Molecular Mechanics Modeling , 2012, Biochemistry.

[67]  K. Korzekwa,et al.  Theoretical studies on cytochrome P-450 mediated hydroxylation: a predictive model for hydrogen atom abstractions , 1990 .

[68]  Johann Gasteiger,et al.  Ligand‐Based Models for the Isoform Specificity of Cytochrome P450 3A4, 2D6, and 2C9 Substrates. , 2007 .

[69]  T. Nikolskaya,et al.  Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[70]  David E. Gloriam,et al.  SMARTCyp: A 2D Method for Prediction of Cytochrome P450-Mediated Drug Metabolism. , 2010, ACS medicinal chemistry letters.

[71]  Kristin P. Bennett,et al.  RS-Predictor: A New Tool for Predicting Sites of Cytochrome P450-Mediated Metabolism Applied to CYP 3A4 , 2011, J. Chem. Inf. Model..

[72]  Andreas Bender,et al.  From in silico target prediction to multi-target drug design: current databases, methods and applications. , 2011, Journal of proteomics.

[73]  Tycho Heimbach,et al.  Prodrugs: design and clinical applications , 2008, Nature Reviews Drug Discovery.

[74]  M. Williamson.  Computational Free Energy Methods for Ascertaining Ligand Interaction with Metabolizing Enzymes , 2014 .

[75]  J. Aqvist,et al.  A new method for predicting binding affinity in computer-aided drug design. , 1994, Protein engineering.

[76]  L. Wienkers,et al.  Predicting in vivo drug interactions from in vitro drug discovery data , 2005, Nature Reviews Drug Discovery.

[77]  B. Testa.  Organic Stereochemistry. Part 8. Prostereoisomerism and the Concept of Product Stereoselectivity in Biochemistry and Xenobiotic Metabolism , 2013 .

[78]  Susumu Goto,et al.  KEGG for integration and interpretation of large-scale molecular data sets , 2011, Nucleic Acids Res..

[79]  M. Hartshorn,et al.  IsoScore: automated localization of biotransformations by mass spectrometry using product ion scoring of virtual regioisomers. , 2009, Rapid communications in mass spectrometry : RCM.

[80]  T. Baillie,et al.  Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: application to studies on the biotransformation of indinavir. , 2004, Analytical chemistry.

[81]  B. Testa,et al.  The Biochemistry of Drug Metabolism – An Introduction , 2007, Chemistry & biodiversity.

[82]  S. Ferguson,et al.  In Vitro Approaches to Study Drug–Drug Interactions , 2014 .

[83]  A. Vedani,et al.  VirtualToxLab - a platform for estimating the toxic potential of drugs, chemicals and natural products. , 2012, Toxicology and applied pharmacology.

[84]  R. Zwanzig.  High‐Temperature Equation of State by a Perturbation Method. I. Nonpolar Gases , 1954 .

[85]  F Peter Guengerich,et al.  Applying mechanisms of chemical toxicity to predict drug safety. , 2007, Chemical research in toxicology.

[86]  D. Wishart.  Advances in metabolite identification. , 2011, Bioanalysis.

[87]  E. Verpoorte,et al.  Microfluidic devices for in vitro studies on liver drug metabolism and toxicity. , 2011, Integrative biology : quantitative biosciences from nano to macro.

[88]  C Roland Wolf,et al.  Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications , 2014, Xenobiotica; the fate of foreign compounds in biological systems.

[89]  Rebecca C Wade,et al.  Multiple, ligand-dependent routes from the active site of cytochrome P450 2C9. , 2012, Current drug metabolism.

[90]  Bernard Testa,et al.  Drug Metabolism for the Perplexed Medicinal Chemist , 2009, Chemistry & biodiversity.

[91]  I. Wilson,et al.  Addressing the challenge of limited sample volumes in in vitro studies with capillary-scale microfluidic LC-MS/MS. , 2011, Bioanalysis.

[92]  B. Testa,et al.  The Biochemistry of Drug Metabolism – An Introduction , 2009, Chemistry & biodiversity.

[93]  Dennis A Smith.  Do prodrugs deliver? , 2007, Current opinion in drug discovery & development.

[94]  Jean-Loup Faulon,et al.  The Signature Molecular Descriptor. 1. Using Extended Valence Sequences in QSAR and QSPR Studies , 2003, J. Chem. Inf. Comput. Sci..

[95]  J. Nicholson,et al.  Host-Gut Microbiota Metabolic Interactions , 2012, Science.

[96]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[97]  Mingshe Zhu,et al.  Drug Metabolite Profiling and Identification by High-resolution Mass Spectrometry* , 2011, The Journal of Biological Chemistry.

[98]  Ola Spjuth,et al.  WhichCyp: prediction of cytochromes P450 inhibition , 2013, Bioinform..

[99]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[100]  K. Youdim,et al.  A review of LC-MS techniques and high-throughput approaches used to investigate drug metabolism by cytochrome P450s. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[101]  K. Berka,et al.  Binding of quinidine radically increases the stability and decreases the flexibility of the cytochrome P450 2D6 active site. , 2012, Journal of inorganic biochemistry.

[102]  Lars Ridder,et al.  Quantum mechanical/molecular mechanical free energy simulations of the glutathione S-transferase (M1-1) reaction with phenanthrene 9,10-oxide. , 2002, Journal of the American Chemical Society.

[103]  G. Schneider,et al.  PocketPicker: analysis of ligand binding-sites with shape descriptors , 2007, Chemistry Central Journal.

[104]  Karel Berka,et al.  Dynamics and hydration of the active sites of mammalian cytochromes P450 probed by molecular dynamics simulations. , 2012, Current drug metabolism.

[105]  Zhengyin Yan,et al.  Unbiased high-throughput screening of reactive metabolites on the linear ion trap mass spectrometer using polarity switch and mass tag triggered data-dependent acquisition. , 2008, Analytical chemistry.

[106]  N Bodor,et al.  Soft drug design: General principles and recent applications , 2000, Medicinal research reviews.

[107]  S. Shaik,et al.  QM/MM Studies of Structure and Reactivity of Cytochrome P450 Enzymes: Methodology and Selected Applications , 2014 .

[108]  Richard A Friesner,et al.  IDSite: An accurate approach to predict P450-mediated drug metabolism. , 2011, Journal of chemical theory and computation.

[109]  Gajendra PS Raghava,et al.  RESEARCH ARTICLE Open Access Research article Prediction of cytochrome P450 isoform responsible , 2022 .

[110]  Lars Olsen,et al.  Ligand-Based Site of Metabolism Prediction for Cytochrome P450 2D6. , 2012, ACS medicinal chemistry letters.

[111]  J. Lindon,et al.  Systems biology: Metabonomics , 2008, Nature.

[112]  P. Kollman,et al.  Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[113]  Chris Oostenbrink,et al.  Free Energy Calculations Give Insight into the Stereoselective Hydroxylation of α-Ionones by Engineered Cytochrome P450 BM3 Mutants , 2012, J. Chem. Inf. Model..

[114]  Alessandro Pedretti,et al.  Reactions and enzymes in the metabolism of drugs and other xenobiotics. , 2012, Drug discovery today.

[115]  P. Rydberg,et al.  Reactivity‐Based Approaches and Machine Learning Methods for Predicting the Sites of Cytochrome P450‐Mediated Metabolism , 2014 .

[116]  Shigeyuki Kitamura,et al.  Current status of prediction of drug disposition and toxicity in humans using chimeric mice with humanized liver , 2014, Xenobiotica; the fate of foreign compounds in biological systems.

[117]  Rebecca C Wade,et al.  The ins and outs of cytochrome P450s. , 2007, Biochimica et biophysica acta.

[118]  L. Olsen.  Drug Metabolism Prediction. Edited by Johannes Kirchmair , 2016 .

[119]  C. E. Peishoff,et al.  A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.

[120]  Richard J. Dimelow,et al.  Prediction of Phosphoglycoprotein (P‐gp)‐Mediated Disposition in Early Drug Discovery , 2014 .

[121]  Li Di,et al.  The role of drug metabolizing enzymes in clearance , 2014, Expert opinion on drug metabolism & toxicology.

[122]  Christoph Steinbeck,et al.  MassCascade: Visual Programming for LC-MS Data Processing in Metabolomics , 2014, Molecular informatics.

[123]  Candace Black-Schaefer,et al.  Automatic mass spectrometry method development for drug discovery: application in metabolic stability assays. , 2004, Rapid communications in mass spectrometry : RCM.

[124]  Lars Ridder,et al.  SyGMa: Combining Expert Knowledge and Empirical Scoring in the Prediction of Metabolites , 2008, ChemMedChem.

[125]  Tingjun Hou,et al.  ADMET Evaluation in Drug Discovery. 11. PharmacoKinetics Knowledge Base (PKKB): A Comprehensive Database of Pharmacokinetic and Toxic Properties for Drugs , 2012, J. Chem. Inf. Model..

[126]  Julio E. Peironcely,et al.  How Do Metabolites Differ from Their Parent Molecules and How Are They Excreted? , 2013, J. Chem. Inf. Model..

[127]  W. Humphreys,et al.  Discovering Drugs Through Biological Transformation: Role of Pharmacologically Active Metabolites in Drug Discovery , 2004 .

[128]  I. Wilson.  Hypernation and Concatenation: Multiple On-Line Spectroscopic Analysis for Drug and Natural Product Characterisation , 2008 .

[129]  D. Schuster,et al.  Pharmacophore‐Based Methods for Predicting the Inhibition and Induction of Metabolic Enzymes , 2014 .

[130]  R Scott Obach,et al.  Pharmacologically Active Drug Metabolites: Impact on Drug Discovery and Pharmacotherapy , 2013, Pharmacological Reviews.

[131]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[132]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[133]  Andrew G. Leach,et al.  Cytochrome P450 Substrate Recognition and Binding , 2014 .

[134]  Russ B. Altman,et al.  PharmGKB: the Pharmacogenetics Knowledge Base , 2002, Nucleic Acids Res..

[135]  Sabcho D Dimitrov,et al.  A systematic approach to simulating metabolism in computational toxicology. I. The TIMES heuristic modelling framework. , 2004, Current pharmaceutical design.

[136]  Lynda B. M. Ellis,et al.  The University of Minnesota Biocatalysis/Biodegradation Database: improving public access , 2009, Nucleic Acids Res..

[137]  David E. Gloriam,et al.  The SMARTCyp cytochrome P450 metabolism prediction server , 2010, Bioinform..

[138]  Sanjay Joshua Swamidass,et al.  RS-WebPredictor: a server for predicting CYP-mediated sites of metabolism on drug-like molecules , 2013, Bioinform..

[139]  Andreas Bender,et al.  Computational Prediction of Metabolism: Sites, Products, SAR, P450 Enzyme Dynamics, and Mechanisms , 2012, J. Chem. Inf. Model..

[140]  Michal Otyepka,et al.  Flexibility of human cytochromes P450: molecular dynamics reveals differences between CYPs 3A4, 2C9, and 2A6, which correlate with their substrate preferences. , 2008, The journal of physical chemistry. B.

[141]  K. Shulman,et al.  Diet and Monoamine Oxidase Inhibitors: A Re-Examination , 1984, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[142]  Didier Rognan,et al.  Computational Profiling of Bioactive Compounds Using a Target-Dependent Composite Workflow , 2013, J. Chem. Inf. Model..

[143]  Lars Ridder,et al.  Molecular determinants of xenobiotic metabolism: QM/MM simulation of the conversion of 1-chloro-2,4-dinitrobenzene catalyzed by M1-1 glutathione S-transferase. , 2007, Biochemistry.

[144]  Duncan Poole,et al.  Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 1. Generalized Born , 2012, Journal of chemical theory and computation.

[145]  Bernard Testa,et al.  The Biochemistry of Drug Metabolism – An Introduction , 2006, Chemistry & biodiversity.

[146]  Lars Olsen,et al.  Predicting Drug Metabolism by Cytochrome P450 2C9: Comparison with the 2D6 and 3A4 Isoforms , 2012, ChemMedChem.

[147]  J. Idle,et al.  The metabolomics of (+/-)-arecoline 1-oxide in the mouse and its formation by human flavin-containing monooxygenases. , 2007, Biochemical pharmacology.

[148]  Lynda B. M. Ellis,et al.  The University of Minnesota Pathway Prediction System: multi-level prediction and visualization , 2011, Nucleic Acids Res..

[149]  R. Abagyan,et al.  METLIN: A Metabolite Mass Spectral Database , 2005, Therapeutic drug monitoring.

[150]  Robert C. Glen,et al.  FAst MEtabolizer (FAME): A Rapid and Accurate Predictor of Sites of Metabolism in Multiple Species by Endogenous Enzymes , 2013, J. Chem. Inf. Model..

[151]  L. Samson,et al.  A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. , 2005, Current drug metabolism.

[152]  A. Stepan,et al.  Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. , 2011, Chemical research in toxicology.

[153]  Yong Wang,et al.  P450 enzymes: their structure, reactivity, and selectivity-modeled by QM/MM calculations. , 2010, Chemical reviews.